AQP4 and neuromyelitis optica: Takahashi and colleagues reported that 91% of NMO and 85% of high-risk syndrome (recurrent LETM) patients are seropositive for AQP4 autoantibodies detected by a similar cell-based IIFA, with a specificity of 100% [34].